genotyped in 440 type 2 diabetes (160 men and 280 women), 58.8 ± 9.2 years old (mean ± SD), BMI 29.
3 ±
3Maniatis, AK;,
Casella, SJ;,
Nadgir, UM;,
Hofman, PL;,
Saenger, P;,
Chertock, ED;,
Aghajanova, EM;,
Korpal-Szczyrska, M;,
Vlachopapadopoulou, E;,
Malievskiy, O;,
Chaychenko, T;,
Cappa, M;,
Song, WJ;,
Mao, M;,
Mygind, PH;,
Smith, AR;,
Chessler, S;,
Komirenko, AS;,
Beckert, M;,
Aimee, D Shu,
Paul, S Thornton (2022) Purpose: The objectives of the ongoing, Phase
3, open-label extension trial enliGHten are to assess
ЛОНГИТЮДНЫЕ ГЕНЕТИЧЕСКИЕ ИССЛЕДОВАНИЯ КОГНИТИВНЫХ ХАРАКТЕРИСТИКМУСТАФИН, Р.Н.,
КАЗАНЦЕВА, А.В.,
ЕНИКЕЕВА, Р.Ф.,
МАЛЫХ, С.Б.,
ХУСНУТДИНОВА, Э.К.,
Mustafin R.N.,
Kazantseva A.V.,
Enikeeva R.F.,
Malykh S.B.,
Khusnutdinova E.K. (2020) мозге генов, таких как BDNF, COMT, CADM2, CYP2
D6, APBA1, CHRNA7, PDE1C, PDE4B, PDE4
D. С физиологическим
Tao, Pan,
Galiullin, D,
Chen, X.L.,
Zhang, W.H.,
Yang, K,
Liu, K,
Zhao, L.Y.,
Chen, X.Z.,
Hu, J.K. (2021) for ASBO were previous abdominal surgery (odds ratio, OR = 2.03), open gastrectomy (OR =
3.12), non